scholarly journals Biochemical Scoring System For Diagnosing Nonalcoholic steatohepatitis

2019 ◽  
Vol 30 (2) ◽  
pp. 58-62
Author(s):  
Sheikh Mohammad Noor E Alam ◽  
Shahinul Alam ◽  
Dulal Chandra Das ◽  
Mamun Al Mahtab
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Scoring System ◽  
Fatty Liver Disease ◽  
Serum Triglyceride ◽  
Gamma Glutamyl Transferase ◽  
Cross Sectional ◽  
Alcoholic Fatty Liver ◽  
Nonalcoholic Fatty Liver ◽  
Glutamyl Transferase

Background: Nonalcoholic fatty liver disease (NAFLD) encompasses a spectrum of conditions ranging from simple steatosis to steatohepatitis, advanced fibrosis, and end stage liver disease. Despite the high prevalence and severity of hepatic illness, NAFLD remains underdiagnosed, because of few symptoms, lack of accurate laboratory markers. Objective: To evaluate a biochemical score for diagnosing non-alcoholic steatohepatitis. Methods: An observational, cross sectional study was carried out for a period of two years in the Department of Hepatology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh. 43 patients of Non-alcoholic fatty liver disease (NAFLD) attending at department of Hepatology were selected and underwent for biochemical investigations and liver biopsy with NAFLD Activity Score (NAS). Results: A biochemical score (TAAG score) assigned 1 point for each parameter (fasting serum triglyceride >ULN, alanine aminotransferase >ULN, AST/ALT ratio (AAR) ≤1 and gamma-glutamyl transferase >ULN) was evaluated. TAAG score ≥3 was present in 32.5% of study population and 40% of NASH patients. It had a sensitivity of 40%, specificity 26% and AUROC 0.54. Conclusion: Biochemical scoring system comprising traditional biomarkers did not significantly predict NASH. Biopsy is the only way to estimate steatohepatitis and/or fibrosis. Bangladesh J Medicine July 2019; 30(2) : 58-62

scholarly journals Pemafibrate Ameliorates Liver Dysfunction and Fatty Liver in Patients with Non-Alcoholic Fatty Liver Disease with Hypertriglyceridemia: A Retrospective Study with the Outcome after a Mid-Term Follow-Up

Diagnostics ◽  
2021 ◽  
Vol 11 (12) ◽  
pp. 2316
Author(s):  
Suguru Ikeda ◽  
Takaaki Sugihara ◽  
Takuya Kihara ◽  
Yukako Matsuki ◽  
Takakazu Nagahara ◽  
...  
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Serum Triglyceride ◽  
Gamma Glutamyl Transferase ◽  
Alcoholic Fatty Liver ◽  
Clinical Criteria ◽  
One Year ◽  
Glutamyl Transferase ◽  
Alcoholic Fatty Liver Disease

Non-alcoholic fatty liver disease (NAFLD) is a chronic liver disease related to metabolic syndrome. No standard pharmacological treatment has yet been established. We retrospectively evaluated the efficacy of pemafibrate in 16 NAFLD patients (11 men and 5 women; median age, 59 years; range, 27–81 years) who had taken pemafibrate for at least one year. They were all diagnosed with fatty liver according to imaging and clinical criteria. They were administered pemafibrate from October 2018 to October 2021 (median, 94 weeks; range, 56–157 weeks). Serum triglyceride was significantly decreased by −41.9% (342.3 ± 54.0 to 198.9 ± 20.4 mg/dL, p < 0.001). Aspartate aminotransferase (AST), alanine aminotransferase, and gamma-glutamyl transferase levels significantly decreased by −42.1% (49.6 ± 7.0 to 28.7 ± 3.4 U/L, p < 0.001), −57.1% (65.1 ± 10.8 to 27.9 ± 3.7 U/L, p < 0.001), and −43.2% (68.9 ± 10.9 to 39.1 ± 5.3 U/L, p < 0.05), respectively. The AST to platelet ratio (APRI) (0.8 ± 0.1 to 0.4 ± 0.1, p < 0.001) and fibrosis based on four factors (FIB-4) index (1.8 ± 0.3 to 1.4 ± 0.2, p < 0.05) also significantly decreased. Liver attenuation (39.1 ± 1.2 to 57.8 ± 2.7 HU, p = 0.028) and liver/spleen ratio (0.76 ± 0.04 to 1.18 ± 0.02, p = 0.012) significantly improved in three patients, as assessed by computed tomography. In conclusion, pemafibrate significantly improves serum triglyceride levels, liver function, FIB-4 index, APRI, and fatty liver in NAFLD patients with hypertriglyceridemia.

scholarly journals Serum Adropin Levels Are Reduced in Adult Patients with Nonalcoholic Fatty Liver Disease

2019 ◽  
Vol 28 (5) ◽  
pp. 463-469 ◽  
Author(s):  
Orkide  Kutlu ◽  
Özgür Altun ◽  
Okan Dikker ◽  
Şerife Aktaş ◽  
Neslihan Özsoy ◽  
...  
Keyword(s):  
Insulin Resistance ◽  
Liver Disease ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
Adult Patients ◽  
Gamma Glutamyl Transferase ◽  
Nonalcoholic Fatty Liver ◽  
Healthy Control ◽  
Glutamyl Transferase

Objectives: Adropin is a novel marker of metabolic syndrome and insulin resistance. The aim of this study was to explore the association of serum adropin levels with hepatosteatosis among adult patients. Materials and Methods: Serum biochemical parameters including liver and renal function tests, insulin levels, and serum adropin levels were compared between adult patients with nonalcoholic fatty liver disease (NAFLD) and healthy control cases. Results: A total of 51 patients with a mean age of 37.9 ± 9.96 years diagnosed with grade 2–3 hepatosteatosis and 30 healthy control cases with a mean age of 34.8 ± 9.5 years were included in the study. Serum adropin levels in the NAFLD group were statistically significantly lower than in the control cases (588.4 ± 261.0 vs. 894.2 ± 301.2, respectively; p < 0.001). The study participants were further subdivided into 2 groups as patients with (n = 35) or without (n = 46) insulin resistance using the serum homeostatic model of assessment-insulin resistance (HOMA-IR). Serum adropin levels were statistically significantly lower in patients with insulin resistance (p < 0.01). There was a negative correlation between adropin levels and serum insulin, HOMA-IR, urea, gamma-glutamyl transferase, total cholesterol, and triglyceride levels. Conclusion: We observed a decrease in serum adropin levels among adult patients with NAFLD. We also found lower levels of serum adropin in patients with insulin resistance, supporting previous data in the literature. Studies investigating the association of adropin levels with other inflammatory parameters are warranted to define its exact role in the pathogenesis of hepatosteatosis.

scholarly journals Vitamin D3 Deficiency in Non-Alcoholic Fatty Liver Disease

2020 ◽  
Author(s):  
Mohammad Mahdi Hayatbakhsh Abbasi ◽  
Mohammad Javad Zahedi ◽  
Sodaif Darvish Moghadam ◽  
Fereshteh Arab Ghahestani ◽  
Fatemeh Karami Robati
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Vitamin D3 ◽  
Fatty Liver Disease ◽  
Demographic Data ◽  
Cross Sectional ◽  
Alcoholic Fatty Liver ◽  
Nonalcoholic Fatty Liver ◽  
Vitamin D3 Deficiency ◽  
Alcoholic Fatty Liver Disease

Regarding the importance of non-alcoholic fatty liver disease (NAFLD) and the high prevalence of vitamin D3 deficiency in different societies. This study aimed to evaluate the distribution of Vit D3 deficiency in individuals with non-alcoholic fatty liver disease. In this cross-sectional study, 122 individuals with nonalcoholic fatty liver disease were selected by a simple sampling method. After collecting demographic data, serum Vit 25(OH) D3 level was measured by the ELFA method. Blood lipids level (TG, cholesterol, HDL, LDL), FBS, AST, ALT, alkaline phosphatase, total and direct bilirubin, albumin, and PT were measured by the enzymatic method. To analyze the data, descriptive and analytical methods and SPSS software version 16 were used. The study cases are comprised of 122 individuals (57.4% male). The average age of cases was 42.4±11.7 years, and the mean of serum Vit D3 level was 19.8±22 ng/dl (3-220 ng/dl). Regarding the serum 25(OH) D3 levels data showed 66.4% of cases were Vit D3 deficient (Vit D3 level< 20 ng/dl), 18% had insufficient level (Vit D3 level=20-30 ng/dl), and the remained 15.6% had sufficient level (Vit D3 level> 30 ng/dl). HDL level was higher in individuals with 25(OH) D3 sufficiency compared to those with 25(OH) D3 insufficiency and Vit D3 deficiency (P=0.019). There was no significant relationship between serum Vit D3 level and other investigated variables. The results of this study indicated that most individuals with non-alcoholic fatty liver disease had Vit D3 deficiency. Further studies are suggested.

scholarly journals Association of circulating adipsin with nonalcoholic fatty liver disease in obese adults: a cross-sectional study

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Jinhua Zhang ◽  
Kangli Li ◽  
Lingling Pan ◽  
Fei Teng ◽  
Peizhen Zhang ◽  
...  
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Protective Factor ◽  
Fasting Glucose ◽  
Enzyme Linked Immunosorbent Assay ◽  
Obese Adults ◽  
Cross Sectional ◽  
Alcoholic Fatty Liver ◽  
Nonalcoholic Fatty Liver

Abstract Background As a secreted adipokine, adipsin has been recently shown to play a pivotal role in metabolic disorders. However, information regarding the association of circulating adipsin with non-alcoholic fatty liver disease (NAFLD) in humans is scant. Methods We recruited 1163 obese adult subjects with waist circumference at least 90 cm in men and 80 cm in women from the community. Circulating adipsin levels were measured by enzyme-linked immunosorbent assay. Results Circulating adipsin levels of NAFLD subjects was decreased compared to those in non-NAFLD (p < 0.05). The prevalence of NAFLD with lower levels of serum adipsin was significantly higher than those with higher values (57.6% vs. 50.9%, p < 0.05). Circulating adipsin levels were significantly associated with decreasing levels of fasting glucose and postprandial glucose (both p < 0.001 for interaction) in NAFLD subjects but not in non-NAFLD subjects. The risk of NAFLD was significantly decreased by 21.7% [OR (95% CI): 0.783 (0.679–0.902), p < 0.001], adjusting for age, gender, current smoking, alcohol consumption, physical activity, BMI, systolic BP, fasting glucose, total cholesterol, HDL-c, HOMA-IR, and body fat mass. Importantly, subjects in the lowest quartile of circulating adipsin were 1.88 times more likely to have NAFLD than those in the highest quartile in multivariable logistic regression analyses. However, such associations with circulating adipsin were not noted for metabolic syndrome, abnormal liver enzyme and significant liver fibrosis. Conclusions These results demonstrate that circulating adipsin levels in Chinese obese adults are negatively associated with risk of NAFLD, implying that serum adipsin levels may be a potential protective factor in NAFLD.

scholarly journals Histological Scoring for Nonalcoholic Fatty Liver Disease – A Study in 55 Cases

2014 ◽  
Vol 14 (2) ◽  
pp. 114-118
Author(s):  
Rehana Khanam ◽  
Muhammad Kamal ◽  
Fauzia Jahan ◽  
P. K. Ghosh
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Nonalcoholic Steatohepatitis ◽  
Fatty Liver Disease ◽  
Morphological Changes ◽  
Research Network ◽  
Cross Sectional ◽  
Alcoholic Fatty Liver ◽  
Nonalcoholic Fatty Liver

Background: Steatohepatitis is a pattern of liver injury that may be seen in alcoholic or nonalcoholic liver disease. This morphological changes may occur with obesity, diabetes, the use of certain drugs or it may be idiopathic. The main histopathological features of nonalcoholic steatohepatitis (NASH) include hepatocellular steatosis and ballooning, mixed acute and chronic lobular inflammation and fibrosis. The recently developed histological scoring system for NAFLD by the NASH Clinical Research Network (NASH CRN) is becoming increasingly popular. The  purpose of this study was to develop grading andstaging system and was  based on liver biopsies from 50 patients with Nonalcoholic Steatohepatitis from BSMMU and other clinics of Dhaka city.Objective: This study was done to analyze the histological spectrum and to develop grading and staging system in patients with nonalcoholic fatty liver disease.Methods: This cross sectional study was carried out at Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka, Bangladesh. A total of 55 patients with non-alcoholic fatty liver disease (NAFLD) who fulfilled the inclusion criteria were selected for the study. Liver biopsy was done at hepatology department of BSMMU, and different clinics of the Dhaka City from july 2006 to june 2007. The data of patients along with   histopathological reports were studied.Results: Out of total 55 cases of Nonalcoholic Fatty Liver Disease 33 were male (63.63%) and 22 were female (40%). Mean age of the patient was 37.81±10.80 years. 35 (63.63%) patients were obese. 2 patients (3.63%) were diabetic. Among 55 patients NAFL (steatosis) were diagnosed in 6 patients (10.90%) and NASH in 49 patients (89.09%). Forty two (16.36%) of the 46 Definite NASH biopsy specimen exhibited fibrosis and three had cirrhosis.DOI: http://dx.doi.org/10.3329/jom.v14i2.19638 J Medicine 2013, 14(2): 114-118

scholarly journals Demographic Variables and Histological Scoring of Non-Alcoholic Fatty Liver Disease in a Bangladeshi Population

2014 ◽  
Vol 40 (2) ◽  
pp. 36-40
Author(s):  
N Majid ◽  
MR Rahman ◽  
RC Rajib ◽  
S Shermin ◽  
F Ahmad ◽  
...  
Keyword(s):  
Liver Disease ◽  
Waist Circumference ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Incidental Finding ◽  
Demographic Variables ◽  
Semiquantitative Assessment ◽  
Cross Sectional ◽  
Alcoholic Fatty Liver ◽  
Nonalcoholic Fatty Liver

A cross sectional study was carried out in the Department of Pathology, Dhaka Medical College, Dhaka and Department of hepatology, Bangabandhu Sheikh Mujib Medical University (BSMMU) during the period of July 2007 to June 2009. Total 55 adult subjects of both sexes were included in this study to evaluate the histological pallern of nonalcoholic fatty liver disease (NAFLD) and its relation with demographic variables including age, sex, BMI, obesity and waist circumference. NAFLD is characterized by macrovesicular deposition of fat in liver. It is now days recognized as a major cause of liver disease and has the propensity for progression to fibrosis and cirrhosis. Study subjects with bright echogenic liver on ultrasonography with no history of alcohol consumption and without having hepatitis B and hepatitis C infections were included. All of them undergone liver biopsy and H&E and Masson's Trichrome stain slides were examined to evaluate the grade and stage of lVAFLD. Scoring and semiquantitative assessment of steatosis and NAFLD severity was done according to Kleiner scale known as NAFLD Activity Score (NAS). Among the subjects 24 were male and 31 female. Mean age 41±10. 66 years (range 20 - 65 years), BMI 29.13±3. 79 kg/m2 (range 24.22 - 39.00 kg/m2), mean of male waist circumference 92.03±6.75 cm (range 88-109 cm) and mean of female waist circumference was 90.17±6.6cm (range 80-102 cm). Only BMI correlated significantly with NAS score whereas age, BMI and waist circumference of male and female subjects correlated significantly with stage of fibrosis. The study concludes that in developing countries like Bangladesh the incidental finding of NAFLD is increasing because of change in life style and food habit. DOI: http://dx.doi.org/10.3329/bmj.v40i2.18508 Bangladesh Medical Journal 2011 Vol.40(2): 36-40

scholarly journals Sarcopenia is associated with the presence of nonalcoholic fatty liver disease in Zhejiang Province, China: a cross-sectional observational study

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Yu-Ming Wang ◽  
Ke-Fu Zhu ◽  
Wen-Jing Zhou ◽  
Qin Zhang ◽  
Dan-Feng Deng ◽  
...  
Keyword(s):  
Liver Disease ◽  
Muscle Strength ◽  
Fatty Liver ◽  
Muscle Mass ◽  
Fatty Liver Disease ◽  
Cross Sectional ◽  
Alcoholic Fatty Liver ◽  
Nonalcoholic Fatty Liver ◽  
Logistic Regression Models ◽  
Specific Association

Abstract Background Currently, both non-alcoholic fatty liver disease (NAFLD) and sarcopenia have attracted extensive attention in public health. However, the relationship between NAFLD and sarcopenia remains unclear. This study aimed to clarify the sex-specific association between sarcopenia and NAFLD according to the Asian Working Group for Sarcopenia (AWGS). Methods Dual-energy X-ray absorptiometry (DXA) and hepatic ultrasonography were measured in 578 participants (92 men and 486 women) during their annual health examinations. Multivariate logistic regression models were used to explore the association between NAFLD and sarcopenia with its two components. Results A total of 154 participants (30 men and 124 women) had NAFLD. The prevalence of sarcopenia was higher among the participants with NAFLD than among those without NAFLD (men: 20.0% vs. 9.7%, P = 0.295, women: 15.3% vs. 8.0%, P = 0.019). Low muscle mass (LMM) was independently associated with NAFLD in both men and women (men: odds ratio [OR], 2.88; 95% confidence interval [CI] 1.52–5.46; women: OR, 2.08; 95% CI 1.63–2.67). However, low muscle strength (LMS) was independently associated with NAFLD only in male participants, with an OR of 1.15 (95% CI 1.02–1.28). Conclusion The occurrence of sarcopenia was associated with a higher risk of NAFLD, especially in men, as demonstrated by lower muscle mass and lower muscle strength.

Sign in / Sign up

Export Citation Format

Share Document